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Aspirinandothernonsteroidalanti-inﬂammatorydrugsshoweﬃcacyinthepreventionofcancers.Itisknownthattheycaninhibit
cyclooxygenases, and some studies have shown that they can induce apoptosis. Our objective in this study was to investigate the
mechanism by which aspirin exerts its apoptosis eﬀects in human cervical cancer HeLa cells. The eﬀect of aspirin on the gene
expression was studied by diﬀerential mRNA display RT-PCR. Among the isolated genes, mu-type calpain gene was upregulated
by aspirin treatment. To examine whether calpain mediates the antitumor eﬀects, HeLa cells were stably transfected with the
mammalian expression vector pCR3.1 containing mu-type calpain cDNA (pCRCAL/HeLa),and tumor formations were measured
in nude mice. When tumor burden was measured by day 49, HeLa cells and pCR/HeLa cells (vector control) produced tumors of
2126mm3 and 1638mm3, respectively, while pCRCAL/HeLa cells produced markedly smaller tumor of 434mm3 in volume. The
caspase-3 activity was markedly elevated in pCRCAL/HeLa cells. The increased activity levels of caspase-3 in pCRCAL/HeLa cells,
in parallel with the decreased tumor formation, suggest a correlation between caspase-3 activity and calpain protein. Therefore,
we conclude that aspirin-induced calpain mediates an antitumor eﬀect via caspase-3 in cervical cancer cells.
Copyright © 2008 Sang Koo Lee et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Aspirin and other agents characterized as nonsteroidal anti-
inﬂammatory drugs (NSAIDs) are designed primarily to
decrease pain and inﬂammation. The molecular basis for
actions of NSAIDs is believed to be their ability to inhibit
cyclooxygenase (COX) activity and block the production of
prostaglandins [1]. Among NSAIDs, aspirin and sulindac
can prevent the development of colon cancer and act as an
anti-inﬂammatory agent by their inhibition of prostaglandin
synthesis [2].
Cancer of the uterine cervix is the second leading cause
of death from cancer in women worldwide and also the
most prevalent gynecological malignancy in Korea [3]. We
investigated whether aspirin induced apoptosis in human
cervical cancer HeLa cells. To investigate the mechanism by
which aspirin exerts its apoptosis eﬀects, the eﬀect of aspirin
on the gene expression was studied by diﬀerential mRNA
display RT-PCR (DD RT-PCR). Employing DD RT-PCR
methods, we identiﬁed aspirin-responsive gene and mu-type
calpain, which was conﬁrmed by real-time quantitative PCR.
Calpain is known to possess the proteoglycanase activity
in vitro [4]. Calpain is ubiquitous family of Ca2+-dependent
neutral cysteine proteases. The two isoforms are classiﬁed
according to their Ca2+ requirements: mu-type calpain
and m-type calpain require micromolar and millimolar
concentrations of Ca2+ for activation, respectively. Growing
evidence suggested that calpain may play a central role
in the execution of apoptosis via modulation of caspase-3
activity in glucocorticoid-treated and irradiated thymocytes,
neuronal cells exposed to UV, or MCF-7 breast cancer cells
treated with β-lapachone [5–7].
Further progress in cancer prevention would depend
on understanding the mechanisms through which aspirin
exerts molecular action. However, the molecular mecha-
nisms through which aspirin alters colonic tumorigenesis are
unknown. In this report, we describe a potential mechanism
by which aspirin induces apoptosis in human cervical cancer2 Journal of Oncology
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Figure 1: Morphological characteristics of HeLa cells after aspirin treatment. (a) Cells were treated with various concentrations of aspirin
and grown for 48 hours. For detection of apoptotic morphology, cells were stained with Hoechst 33342 dye and assessed for morphological
signs of apoptosis. The right panel (b) shows the enlarged photograph of apoptotic cells (×40).
cells. To examine whether mu-type calpain mediates antitu-
mor eﬀects in HeLa cells, HeLa cells were stably transfected
with mu-type calpain cDNA. Tumor formation and caspase-
3 activity of stably transfected cells were measured in nude
mice. In this paper, we suggest that aspirin has an antitumor
eﬀect via the expression of mu-type calpain gene in cervical
cancer cells.
2. Methods
2.1. Apoptosis Analysis. Human cervical cancer cells, HeLa,
were plated in a 24-well plate at a density of 1×104 cells/well
and treated with various doses of aspirin. To detect an
apoptotic body, cells were stained with Hoechst 33342 dye
and assessed for morphological signs of apoptosis. The
proportionofcellsinG0/G1,S,andG2/Mwasdeterminedby
ﬂow cytometric analysis of DNA content (Becton Dickinson,
Peterson, NJ, USA). Cell suspension was stained with
propidium iodide. DNA histograms were analyzed using
CELL QUEST software to evaluate cell cycle compartments.
2.2. Diﬀerential mRNA Display RT-PCR and Cloning. Total
RNA was extracted from cells with TRizol reagent (Invit-
rogen, Carlsbad, Calif, USA), following the protocol that
was provided. Cell monolayers were washed with PBS, and
1mLofTRizol/10 6 cells with 4 units of RNase inhibitor were
added. For each sample, 2μgo fR N Aw e r et r e a t e dw i t h
DNasel(Roche,Basel,Switzerland)at37
◦Cfor30minutesto
remove contaminating DNA. One-base-anchored oligo-dT
primerswereusedtoreversetranscribedtotalRNAintoﬁrst-
strand cDNA, which were ampliﬁed subsequently by PCR
using the arbitrary upstream primers. PCR products were
labeled with 2μCi of α[32P]dCTP (Amersham, Arlington,
Ill, USA), and analyzed on a 6% polyacrylamide-urea gel.
The cDNA bands that were unique to control or aspirin-
treated cells were cut out of the gel, eluted, and reampliﬁed
by PCR. The candidate cDNA was cloned into pGEM-T
vector (Promega, Madison, WI, USA). Plasmid with insert
was puriﬁed and sequenced after performing PCR reactions.
2.3. Real-Time Quantitative PCR. We relied on the TaqMan
assay (Perkin-Elmer model 7700; Foster City, CA, USA) to
quantitate the amount of calpain mRNA. The forward and
reverse primers and the FAM-tagged probe used for the mu-
type calpain gene in the assay were 5 -GGATGTCATTCC-
GAGACT, 5 -CTCGTAGACCGCGAAG, and 5 -6FAM-
TCTGCAACCTCACACCCGAC-TAMRA, respectively. The
forward and reverse primers and FAM-tagged probe used
for the ß-actin gene were 5 -AACTTGAGATGTATGAAG-
GCTTTTGG, 5 -TTTTTTTTTTTTTTTTTTTTTTTTTTT-
TTAAG, and 5 -6FAM-CAACTGGTCTCAAGTCAGTGTA-
CAGGTAAGCCCT-TAMRA, respectively. To measure the
relative abundance of the calpain gene in any given RNA
sample, the ampliﬁcation value derived using the calpain
sequence was divided by the ampliﬁcation value using the ß-
actin sequence.
2.4. Transfection of Calpain cDNA and Cell Growth Assay.
The mu-type calpain cDNA was retrieved with the following
primers: forward 5 -AGGATGTCGGAGGAGA and reverseJournal of Oncology 3
5 -CCAGTACACAAGTCCCT. PCR reaction products were
cloned into pCR3.1 vector (Invitrogen). The vector pCR or
recombinant pCRCAL was stably transfected into HeLa cells
by liposome. Control, vector-transfected (pCR/HeLa), and
calpain-transfected cells (pCRCAL/HeLa) were counted by
the trypan blue exclusion assay and Coulter counter (Coulter
Corporation, FL, USA) for measuring stably transfected cell
growth. Cell number was presented as the mean ± S.E. ﬁve
experiments.
2.5. Enzymatic Assay for Caspase-3 Activity. Cells (1.5 × 106)
were plated in cell culture dishes (100mm) and allowed to
attach for 48 hours under cell culture conditions. Then the
cells were treated and the activity of caspase-3 was measured
using the ﬂuorogenic enzyme substrates, z-DEVD-AFC
(Molecular Probes, Eugene, Ore, USA). Samples were read
in a ﬂuorometer equipped with a 400nm excitation ﬁlter
and 505nm emission ﬁlter. Enzyme activity was expressed
as relative ﬂuorescence units/mg of protein. The arbitrary
values were presented as the mean ±S.E. ﬁve experiments.
2.6. Tumorigenicity. Balb/c nu/nu mice, 4–6 weeks of age,
were acclimated and caged in groups of ﬁve. HeLa,
pCR/HeLa, and pCRCAL/HeLa cells (1.5 × 107)w e r e
injected subcutaneously into the right ﬂank of the nude
mouse. The mean tumor diameter was measured by dial
caliper, and the volume was calculated by the formula:
volume (mm3) = (square root of width ×length)
3.M e a n
values of ﬁve mice/group ±SEM are shown. The experiment
was repeated three times and performed according to the
guidelines of the Animal Experimental Committee, National
Institute of Health, South Korea. Statistical calculations were
performed using the Microsoft Excel 97 program (1998;
Microsoft Co., Redmond ,Wash, USA) to estimate P-value.
The signiﬁcance level (P-value) is determined using the
Student’s t-test. Probability values <.05 were considered
signiﬁcant.
3. Results
3.1. Apoptosis in Aspirin-Treated HeLa Cells. We performed
DNA synthesis assay to study the eﬀects of aspirin on HeLa
cells. HeLa cells were treated in 1, 2, or 3mM aspirin.
Aspirin inhibited growth of cervical cancer cells in a time-
and concentration-dependent manner (data not shown).
HeLa cells were then assessed for apoptosis. Aspirin-induced
morphological changes were evident in a concentration-
dependent manner (see Figure 1). Cells treated with aspirin
became sparse, long squared, and detached from the dishes.
Cell number was also decreased. Apoptotic bodies (indicated
by white arrows in Figure 1) were shown after aspirin
treatment.Toshowapoptosisinthecellstreatedwithaspirin,
ﬂow cytometry analysis was performed. The population of
sub-G1 phase was changed from 1.2 to 18.9% in cells treated
with 1mM aspirin for 48 hours. That of sub-G1 phase at 2
and 3mM was in the similar range.
3.2. Identiﬁcation of Calpain Gene in Aspirin-Treated HeLa
Cells. AfterHeLa cellsweretreatedwithaspirin for48 hours,
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Figure 2: Real-time quantitative RT-PCR for calpain gene in
aspirin-treated HeLa cells. To measure the relative abundance of
mu-type calpain gene in a given RNA sample, the ampliﬁcation
value derived using calpain gene was divided by the ampliﬁcation
value using the β-actin sequence. ∗, P<. 05 control versus treated
group.
we performed diﬀerential display RT-PCR and selected
diﬀerentially expressed genes, which was expressed with
absolute diﬀerence between control and aspirin-treated cells.
The genes were identiﬁed with DNA sequencing. One of the
upregulated genes is mu-type calpain. Expression of calpain
mRNA was conﬁrmed by real-time quantitative PCR (see
Figure 2). Calpain gene was highly expressed in aspirin-
treated HeLa cells in a concentration-dependent manner.
Calpain gene was upregulated by 4.4, 6, and 8.8 folds in the
1, 2, and 3mM aspirin-treated HeLa cells, respectively.
3.3. Tumorigenicity of Calpain Gene Product. We have cloned
mu-type calpain cDNA into pCR3.1 vector. The vector
pCR or recombinant pCRCAL was stably transfected into
HeLa cells (pCR/HeLa cell or pCRCAL/HeLa cell). To
assess whether change of cell biology was caused after
gene transfection, we measured cell proliferation. pCR-
CAL/HeLa cells appeared to have a markedly diﬀerent
growth pattern compared with HeLa cells and pCR/HeLa
cells (see Figure 3(a)). To establish a relationship between
calpain and caspase-3, caspase-3 activities were measured.
As shown in Figure 3(b), caspase-3 activity was elevated in
pCRCAL/HeLa cells. The markedly increased activity levels
of caspase-3 in pCRCAL/HeLa cells suggest a correlation
of caspase-3 activity and calpain protein. In investigation
of calpain role in the tumorigenicity, we evaluated tumor
progression in nude mice. 1.5 × 107 stably transfected cells
were subcutaneously injected into the ﬂank of the mouse.
When tumor burden was measured by day 49, HeLa cells
and pCR/HeLa cells produced tumors of 2126 ± 163mm3
and 1638±213mm3, respectively, while pCRCAL/HeLa cells
producedmarkedlysmalltumorof434±206mm3 involume
(see Figure 3(c)). The experiment was repeated three times
with similar results. Tumor growth was reduced by calpain
gene expression.
4. Discussion
We report that aspirin inhibited the proliferation of cer-
vical adenocarcinoma cells in a time- and dose-dependent4 Journal of Oncology
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Figure 3: In vitro characteristics and tumorigenicity of stably
transfected cells. (a) Cell proliferation. Control (HeLa), vector-
transfected (pCR/HeLa), and mu-type calpain-transfected cells
(pCRCAL/HeLa) were counted by the trypan blue staining and
Coulter counter. (b) Caspase-3 activities. Caspase-3 activities were
measured by analyzing the ﬂuorometric cleavage of substrates, z-
DEVD-AFC. RFU, relative ﬂuorescence units. (c) Groups of ﬁve
mice each were injected with HeLa, pCR/HeLa, and pCRCAL/HeLa
cells (1.5 × 107 in 0.1mL saline) subcutaneously inducing solid
tumor. The tumor volume was evaluated on the 20th, 34th,
41st, and 49th day onwards after tumor cell induction. The
tumor volume was calculated by the formula: volume (mm3) =
(square root of width ×length)
3. Mean values of ﬁve mice/group
±SEM are shown. The experiment was repeated three times with
similar results. ∗, P<. 05 HeLa versus pCRCAL/HeLa.
manner. This agrees with other studies showing that aspirin
inhibitedtheproliferationofcancercells[2,4,8–12].Aspirin
has antitumor eﬀects in the colon through induction of
quiescence and apoptosis [13]. Apoptosis was shown to be
responsible for the cell growth inhibitory eﬀects of aspirin
in HT29 human colon carcinoma cells. Our morphological
observation of nuclear condensation after aspirin treatment
suggests that aspirin increases apoptosis in cervical cancer
cells (see Figure 1). These results demonstrate that aspirin is
aneﬀectiveantitumordrugthatinducesapoptosisincervical
cancer cells.
A few molecular mechanisms of aspirin have been
proposed. One of these mechanisms is COX-independent
[14, 15]. It is well known that activation of p53 expression
is involved [16]. In this study, we have shown that aspirin
induces the calpain gene and calpain gene activation inhibits
the tumor formation. These results support the previous
ﬁndings that aspirin induces apoptosis by the regulation of
bcl-2 and caspase-3 in human cervical cancer cells [3, 17].
Therefore,aspirinmightplayrolesintheinhibitionoftumor
formation through activation of calpain gene.
Calpain is a calcium-dependent cysteine protease that
is implicated in calcium-dependent cell death [17, 18].
Calpain plays an essential role in apoptotic commitment
by cleaving Bax and generating the Bax/p18 fragment,
which in turn mediates cytochrome c release and initiates
the apoptotic execution [19]. Calpain activation plays a
critical role in cancer cell adhesion and motility [20]; and
calpain could be related to a therapeutic strategy targeting
multiple disease states [21–24]. In our experiments, caspase-
3 activity was increased in the calpain-transfected HeLa
cells, suggesting a correlation of calpain and caspase-3 (see
Figure 3(b)). The involvement of caspase-3 in the calpain
action is in agreement with the results in the photoreceptor
cell, where calpain executes apoptosis via modulation of
caspase-3activity[25].Accompanyingtheincreasedcaspase-
3 activity, tumor growth was reduced by calpain gene
expression, leading to the role of calpain as an apoptosis
mediator (see Figure 3(c)). Fushimi et al. have analyzed
calpain release from cultured chondrocytes stimulated by a
proinﬂammatory cytokine, tumor necrosis factor-α (TNF-
α)[ 4]. The eﬀects of NSAIDs on calpain release were
also examined. However, their results were in contrast to
our expectation. NSAIDs examined (aspirin, loxoprofen-
SRS, diclofenac sodium, indomethacin, and NS398) potently
inhibited TNF-α-induced release of calpain [4]. In addition,
they showed that PGE2 alone failed to stimulate, but it
signiﬁcantly augmented the release of calpain in the presence
of 1ng/mL TNF-α in HCS-2/8 cells. Moreover, inhibition of
calpain release by an NSAID, loxoprofen-SRS, was signiﬁ-
cantly reversed by 100nM PGE2. Therefore, further studies
are necessary to clarify the relationship implicated in the
aspirin treatment.
5. Conclusion
Aspirin causes growth inhibition of cervical cancer cells
through activation of apoptosis. We suggest that aspirinJournal of Oncology 5
may have cancer-preventing eﬀects through calpain gene
expression, which leads to caspase-3 activation.
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